TY - JOUR
T1 - Plerixafor and Filgrastim XM02 (Tevagastrim
®) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation
AU - Andreola, Giovanna
AU - Babic, Aleksandra
AU - Rabascio, Cristina
AU - Negri, Mara
AU - Martinelli, Giovanni
AU - Laszlo, Daniele
PY - 2012/2
Y1 - 2012/2
N2 - Plerixafor, a CXCR4 antagonist, has shown to be effective in increasing the number of circulating stem cells, even in patients failing a previous mobilisation attempt. Recently a number of non-glycosylated recombinant human granulocyte-colony stimulating factor (G-CSF) has been clinically approved for the same indications as the originator G-CSF for comparable safety and efficacy and their reduced cost. In an attempt to provide a less toxic strategy, 14 patients affected by haematological malignancies (non-Hodgkin's lymphoma=4, Hodgkin's disease=2 and multiple myeloma=8), received the combination of biosimilar filgrastim and plerixafor as a first line mobilising strategy. The median number of circulating CD34+ cells on day 4 was 16 (3-42); Plerixafor was administered to all, but one patient who had already 42 CD34+ cells per μL on day 4. On day 5, after plerixafor administration, the median number of circulating CD34+ cells had raised to 60 per μL (14-138). All the patients underwent leukapheresis and were able to collect a number of CD34+ cells ≥2.0×10
6/kg in a median number of procedures of one. Although preliminary, these data show the combination of biosimilar filgrastim and plerixafor is effective and provides a non-toxic approach to mobilise stem cells.
AB - Plerixafor, a CXCR4 antagonist, has shown to be effective in increasing the number of circulating stem cells, even in patients failing a previous mobilisation attempt. Recently a number of non-glycosylated recombinant human granulocyte-colony stimulating factor (G-CSF) has been clinically approved for the same indications as the originator G-CSF for comparable safety and efficacy and their reduced cost. In an attempt to provide a less toxic strategy, 14 patients affected by haematological malignancies (non-Hodgkin's lymphoma=4, Hodgkin's disease=2 and multiple myeloma=8), received the combination of biosimilar filgrastim and plerixafor as a first line mobilising strategy. The median number of circulating CD34+ cells on day 4 was 16 (3-42); Plerixafor was administered to all, but one patient who had already 42 CD34+ cells per μL on day 4. On day 5, after plerixafor administration, the median number of circulating CD34+ cells had raised to 60 per μL (14-138). All the patients underwent leukapheresis and were able to collect a number of CD34+ cells ≥2.0×10
6/kg in a median number of procedures of one. Although preliminary, these data show the combination of biosimilar filgrastim and plerixafor is effective and provides a non-toxic approach to mobilise stem cells.
KW - Biosimilar granulocyte colony-stimulating factor
KW - CD34+ cells
KW - Plerixafor
KW - Stem cell mobilisation
UR - http://www.scopus.com/inward/record.url?scp=84855836072&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855836072&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0609.2011.01719.x
DO - 10.1111/j.1600-0609.2011.01719.x
M3 - Article
C2 - 21992403
AN - SCOPUS:84855836072
VL - 88
SP - 154
EP - 158
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 2
ER -